Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study

INTRODUCTION: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX). METHODS: This was a 52-week, randomized, double-blind, placebo controlled, phase III st...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yue, Xu, Jianhua, Xu, Jian, Li, Xingfu, Hu, Jiankang, Li, Xiangpei, Zhang, Xiao, He, Dongyi, Bao, Chunde, Li, Zhijun, Wang, Guochun, Zerbini, Cristiano A. F., Spindler, Alberto J., Kannowski, Carol L., Wu, Hanjun, Ji, Fei, Zhan, Lujing, Liu, Mengru, Li, Zhanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research (Extended Report)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064513/
https://www.ncbi.nlm.nih.gov/pubmed/33959198
http://dx.doi.org/10.1177/1759720X211006964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064513/
https://www.ncbi.nlm.nih.gov/pubmed/33959198
http://dx.doi.org/10.1177/1759720X211006964

Ejemplares similares